A/S has had its credit rating outlook revised to negative from stable at S&P Global, due to substantial impairments of Danish ...
HealthDay on MSN1d
FDA Approves Spravato Nasal Spray for Treatment-Resistant DepressionThe U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback